Researchers have determined the structure of a human antibody bound to the Zika virus, revealing details about how the antibody interferes with the infection mechanism - findings that could aid in development of antiviral medications. The new findings also suggest the antibody might be especially effective because a lower concentration than expected is needed to inhibit a key mechanism of infection, making it more potent than previous antibodies studied.

Researchers have discovered one of the reasons why broccoli may be good for your health. They found that sulforaphane, a dietary compound from broccoli that's known to help prevent prostate cancer, may work through its influence on long, non-coding RNAs. This is another step forward in a compelling new area of study on the underlying genetics of cancer development and progression.

The first of a new class of medication that delivers a combination of drugs by nanoparticle may keep melanoma from becoming resistant to treatment, according to Penn State College of Medicine researchers. CelePlum-777 combines a special ratio of the drugs Celecoxib, an anti-inflammatory, and Plumbagin, a toxin. With the drug, the cells have difficulty overcoming the effect of having more than one active ingredient.

Researchers from the University of Washington School of Public Health have been peeking into kitchens - via interviews - for years now. They've just published results showing people who cook at home more often are likely to eat a healthier overall diet. The measurement used to define a healthy diet is called the Healthy Eating Index. It gauges whether a person's diet is giving them the right combination of fruits, vegetables and other elements.

Scientists from the University of Liverpool have shown that phage therapy could offer a safe and effective alternative to antibiotics in the treatment of Cystic Fibrosis lung infections. Chronic lung infections caused by the bacterium Pseudomonas aeruginosa are becoming increasingly difficult to treat due to antimicrobial resistance (AMR). With limited alternative therapeutic options available this has led to a renewed interest in (bacterio)phage therapy.

In 2001 the U.S. Food and Drug Administration granted priority review for imatinib mesylate, sold under the name Gleevec®*, as an oral therapy for patients with chronic myeloid leukemia, or CML. The New England Journal of Medicine has published results from a nearly 11-year follow-up study, that showed an estimated overall survival rate of 83.3 percent.

Houston Methodist researchers have identified an immune pathway that promotes the formation of a cell that can develop into new tissues and organs. In a new study published in the journal Stem Cells, a team led by John P. Cooke, M.D., Ph.D., chair of Cardiovascular Sciences, Houston Methodist Research Institute, described how activation of innate immunity enhances nuclear reprogramming, one of the first steps in tissue regeneration, or the formation of new tissues and organs from a single cell in the body.